{
    "clinical_study": {
        "@rank": "164970", 
        "arm_group": {
            "arm_group_label": "CHC Patients on triple combination treatment"
        }, 
        "biospec_descr": {
            "textblock": "Blood serum used to analyze levels of hepatitic c virus (HCV) RNA"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This prospective, national, multicenter, non-interventional study will examine the use of\n      triple combination therapy with boceprevir, Pegasys and ribivarin in re-treating patients\n      with genotype 1 CHC infection. Dosing and treatment duration are at the discretion of the\n      investigator in accordance with local clinical practice and local labeling. Patients will be\n      observed for the duration of their triple combination therapy and for up to 24 weeks\n      thereafter."
        }, 
        "brief_title": "An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Pegasys and Ribivarin in the Re-Treatment of Chronic Hepatitis C Patients", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or over\n\n          -  Genotype 1 CHC infection\n\n          -  Prior unsuccessful treatment with Peginterferon plus ribivarin (null-response,\n             partial response and relapsed patients)\n\n          -  Receiving triple combination therapy with boceprevir, Pegasys and ribivarin according\n             to standard of care and in line with local labeling\n\n          -  Enrolment in the study no later than 4 weeks after start of triple combination\n             therapy (including Pegasys and ribivarin lead-in phase)\n\n          -  Given consent to take part in the study\n\n        Exclusion Criteria:\n\n          -  Na\u00efve patients not responding to Peginterferon plus ribivarin at week 4 (HCV RNA drop\n             < 1 log10) or at week 12 (HCV RNA >/= 15 IU/mL) and switching to triple combination\n             therapy with boceprevir"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with genotype 1 chronic hepatitis C (CHC) infection taking triple combination\n        therapy (boceprevir, Pegasys and ribavirin)"
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118597", 
            "org_study_id": "ML29278"
        }, 
        "intervention_browse": {
            "mesh_term": "Peginterferon alfa-2a"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 16, 2014", 
        "number_of_groups": "1", 
        "official_title": "Non-interventional Study to Observe Triple Combination Therapy With Boceprevir Plus Peginterferon Alfa-2a Plus Ribavirin for Re-treatment of Chronic Hepatitis C in Hungary", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML29278 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Hungary: Gyogyszereszeti \u00e9s Egeszsegugyi Minoseg- es Szervezetfejlesztesi Intezet Orszagos Gyogyszereszeti Intezet"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sustained virological response 24 (SVR24), defined as percentage of patients with HCV RNA < 15 IU/mL after the 24-week follow-up", 
            "safety_issue": "No", 
            "time_frame": "At Week 72"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118597"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Virological response (HCV RNA < 15 IU/mL)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4, 8, 12, 24, and 48"
            }, 
            {
                "measure": "Virological breakthrough, defined as either HCV RNA >/= 15 IU/mL in patients with prior virological response or as an increase in RCV RNA >/= 1 log10 above nadir", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Virological relapse defined as HCV RNA >/= 15 IU/mL  during the treatment free follow-up period in patients with virological response at the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "Weeks 49 to 72"
            }, 
            {
                "measure": "Incidence of treatment discontinuation due to futility, defined as: HCV RNA drop < 3 log10 at Week 8, HCV RNA >/= 100 IU/mL at Week 12, or HCV RNA >/= 15 IU/mL at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Incidence of treatment discontinuation", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "measure": "Predictive value of patient demographics", 
                "safety_issue": "No", 
                "time_frame": "Screening (before Week 1)"
            }, 
            {
                "measure": "Predictive value of liver fibrosis", 
                "safety_issue": "No", 
                "time_frame": "Screening (before Week 1)"
            }, 
            {
                "measure": "Predictive value of HCV disease characteristics", 
                "safety_issue": "No", 
                "time_frame": "Screening (before Week 1)"
            }, 
            {
                "measure": "Predictive value of previous virological response (null-response, partial response, or relapse)", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}